Delayed Quote. Delayed  - 06/24 11:31:14 am
1.535CHF -0.97%

Press Release: Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021

05/03/2021 | 01:00am
   Geneva, Switzerland, May 3, 2021 -- 
Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage 
pharmaceutical company pioneering allosteric modulation-based drug 
discovery and development, today announced that it will issue its Q1 
2021 financial results on Wednesday May 5, 2021. Tim Dyer, CEO, Roger 
Mills, CMO and Robert Lütjens, Head of Discovery Biology will 
provide a business update and review its pipeline during a 
teleconference and webcast for investors, analysts and the media on 
Wednesday, May 5, 2021 at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 
   Title:                Addex to Announce Q1 2021 Financial Results 
   Date:               May 5, 2021 
   Time:               16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) 
   Joining the Conference Call: 
   1: In the 10 minutes prior to the call start time, call the appropriate 
participant dial-in number. 
   Dial-In Numbers: 
   -- Switzerland                +41 44 580 65 22 
   -- UK                                +44 20 30 09 24 70 
   -- U.S.A                        +1 87 74 23 08 30 
   -- Other Countries: 
   2: Provide the Operator with the Participation Pin Code: 64754025# 
   Link to live event online: 
   1: In the 10 minutes prior to the call start time, sign in online by 
following this Webex 
   2: Password: Welcome 
   About Addex Therapeutics: 
Therapeutics is a clinical-stage pharmaceutical company focused on the 
development and commercialization of an emerging class of novel orally 
available small molecule drugs known as allosteric modulators for 
neurological disorders. Allosteric modulators offer several potential 
advantages over conventional non-allosteric molecules and may offer an 
improved therapeutic approach to conventional "orthosteric" small 
molecule or biological drugs. Addex's allosteric modulator drug 
discovery platform targets receptors and other proteins that are 
recognized as essential for therapeutic intervention. Addex's lead 
product candidate, dipraglurant (mGlu5 negative allosteric modulator or 
NAM), is poised to start a pivotal registration clinical trial for 
Parkinson's disease levodopa induced dyskinesia (PD-LID) in Q2 2021. 
Addex is also investigating dipraglurant's therapeutic use in 
blepharospasm (a type of dystonia), for which a clinical trial is 
expected to be initiated in Q2 2021. Addex's third clinical program, 
ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in 
collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter 
a phase 2a proof of concept clinical trial for the treatment of epilepsy 
in Q2 2021. Addex's GABAB PAM program has been licensed to Indivior PLC, 
which is focused on development for the treatment of addiction. 
Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, 
mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's 
disease and mGlu3 PAM for neurodegenerative disorders. Addex shares are 
listed on the SIX Swiss Exchange and American Depositary Shares 
representing its shares are listed on the NASDAQ Capital Market, and 
trade under the ticker symbol "ADXN" on each exchange. 
   Press Contacts: 
Tim Dyer                   Mike Sinclair              James Carbonara 
 Chief Executive Officer    Partner, Halsin Partners   Hayden IR 
 Telephone: +41 22 884 15   +44 (0)20 7318 2955        +1 (646)-755-7412 
   Forward Looking Statements: 
   This press release contains forward-looking statements within the 
meaning of the Private Securities Litigation Reform Act of 1995, as 
amended, including in respect of the anticipated initiation and progress 
of clinical trials and preclinical studies, and its future financing 
activities. The words "may," "will," "could," "would," "should," "expect, 
" "plan," "anticipate," "intend," "believe," "estimate," "predict," 
"project," "potential," "continue," "target" and similar expressions are 
intended to identify forward-looking statements, although not all 
forward-looking statements contain these identifying words. Any 
forward-looking statements in this press release, are based on 
management's current expectations and beliefs and are subject to a 
number of risks, uncertainties and important factors that may cause 
actual events or results to differ materially from those expressed or 
implied by any forward-looking statements contained in this press 
release, including, without limitation, uncertainties related to market 
conditions. These and other risks and uncertainties are described in the 
Company's Annual Report on Form 20-F filed with the SEC on March 11, 
2021, as well as market conditions and regulatory review. 
   Any forward-looking statements contained in this press release represent 
Addex Therapeutics' views only as of the date hereof and should not be 
relied upon as representing its views as of any subsequent date. Addex 
Therapeutics explicitly disclaims any obligation to update any 
forward-looking statements, except as required by law. 

(END) Dow Jones Newswires

May 03, 2021 01:00 ET (05:00 GMT)

Copier lien
6d ago
7d ago
7d ago